Good evening everybody. I think that's going to be an extremely hard act to follow. And you know what my wife said to me a few weeks ago when I told her I was coming to do a TEDex talk at DBS.Why would you do that. You know what she said next. She said, "You should put your hands in your pocket. You should strut around. You should wear a black turtleneck and jeans." I didn't do any of that.um probably much to my detriment when I go home tonight. Why you say happy life, happy wife, right. But what I'm going ...

Summary of Key Points from the Conference Call Industry Overview - **Industry Focus**: Medtech/Life Sciences, specifically surgical robotics, brain-computer interfaces (BCIs), and AI diagnostics [2][4][15] - **Outlook for 2026**: Anticipated as a catalyst-rich year with significant updates expected to drive private investor interest [2] Core Themes and Insights Surgical Robotics - **Market Dynamics**: 2026 is viewed as pivotal for surgical robotics, with companies like Medtronic (MDT), CMR Surgical, and Johnson & Johnson (JNJ) launching competitive products [5][10] - **Growth Potential**: Expansion into high-volume, low-acuity procedures at ambulatory surgical centers (ASCs) is seen as a critical growth area [5][18] - **Investor Confidence**: Competitive dynamics will be crucial for investor confidence in the market, particularly regarding the ability of new entrants to compete with established players like Intuitive Surgical (ISRG) [5][10] Brain-Computer Interfaces (BCIs) - **Investor Interest**: Significant investor interest in BCIs, with over $1 billion raised in 2025 [27] - **Neuralink's PRIME Study**: Follow-up data from Neuralink's PRIME study in 2026 is expected to be a key catalyst for investor confidence in the efficacy of BCIs [5][10][31] - **Competition from China**: Increased government investment in BCIs in China poses potential challenges for US companies, raising questions about scalability and competition [9][25][26] AI Diagnostics - **Potential Benefits**: AI diagnostics could lead to earlier disease detection, improved patient outcomes, and increased procedure volumes [31][37] - **Challenges**: Reimbursement hurdles and integration into existing workflows remain significant challenges for widespread adoption [31][37] - **Provider ROI**: Increased procedures and workflow efficiencies are expected to provide financial incentives for hospital systems to adopt AI diagnostic technologies [31][37] Key Data Points Venture Capital Raises in 2025 - **Top VC Raises in Medtech**: - Neuralink: $650 million (Series E) [3] - Impulse Dynamics: $242 million [3] - Noah Medical: $230 million (Series B1) [3] - Synchron: $200 million (Series D) [3] - Lumicell: $198 million [3] - **Overall VC Deal Flow**: Down approximately 30% compared to 2023, but an increase from 2024 [21] Additional Insights - **Surgical Robotics Pricing Model Shift**: A shift towards a pay-per-procedure model is anticipated, focusing on revenue from disposables rather than the initial robot purchase [17][18] - **Emerging Technologies**: Interest in non-surgical and minimally invasive implants is growing, with advancements in AI and hardware making these technologies more viable [27] - **Healthcare System Constraints**: Capital constraints in hospital systems may favor multi-purpose robotic systems that can be utilized across various procedures and specialties [15] Conclusion - The medtech industry is poised for significant developments in 2026, particularly in surgical robotics, brain-computer interfaces, and AI diagnostics. Investor confidence will hinge on competitive dynamics, technological advancements, and the ability to navigate reimbursement and integration challenges.

Group 1 - Stryker Corporation (NYSE:SYK) is recognized as a leading healthcare AI stock, with Citi adjusting its price target from $455 to $420 while maintaining a Buy rating [1][2] - The company declared a quarterly dividend of $0.88 per share, which is a 4.8% increase from the previous dividend paid in October 2025, resulting in an annualized dividend of $3.52 per share [2] - Stryker appointed Spencer Stiles as President and Chief Operating Officer, effective January 1, 2026, who will oversee global businesses and corporate strategy [3] - Dylan Crotty will be promoted to Group President of Orthopaedics, succeeding Stiles, and is noted for his operational leadership [4] Group 2 - Stryker designs and manufactures medical technologies in orthopedics, surgical equipment, and neurotechnology, utilizing AI in surgical robotics, predictive analytics, enhanced imaging, inventory management, and remote monitoring [5]